Acanthosis nigricans (AN) is a visible marker of insulin resistance — characterised by dark, velvety skin patches, typically on the neck, armpits, groin, and skin folds. It is not a skin disease. It is a metabolic sign.
When insulin levels remain chronically elevated (hyperinsulinemia), they trigger a cascade: increased IGF-1 signalling → hyperkeratinization (thickened stratum corneum) → melanin dysregulation → the characteristic dark, velvety appearance.
For Indian skin (Fitzpatrick V–VI), AN is particularly common due to genetic predisposition to insulin resistance, higher prevalence of PCOS and metabolic syndrome, and sun-driven inflammatory burden that amplifies hyperinsulinemia's effects. This guide covers: what AN is at the cellular level, the insulin signalling pathways driving it, why it appears in dark skin specifically, and evidence-informed skincare approaches.
This article is for educational purposes only and does not constitute medical advice. Individual skin biology varies. If you suspect acanthosis nigricans, consult a dermatologist or metabolic health physician for proper evaluation and management.
If you're searching for what acanthosis nigricans is, whether it's reversible, how insulin drives the appearance, why it's more common in Indian skin, or what skincare can support metabolic healing — this guide covers the complete pathophysiology, the mechanisms specific to darker skin, and evidence-informed ingredient strategies.
Acanthosis nigricans is a cutaneous manifestation of systemic insulin resistance. It appears as dark, velvety, thickened skin patches, typically symmetrical, in flexural regions (neck, axillae, groin, inframammary). The texture is distinctly raised and papillated (bumpy), not smooth. Histologically, AN is characterised by hyperkeratinization, acanthosis (thickening of the epidermis), and melanin overproduction in response to chronically elevated insulin and IGF-1 signalling. It is not a disease of the skin; it is a visible sign of metabolic dysfunction.
- Acanthosis nigricans is a metabolic sign of insulin resistance, not a primary skin disease. Topical treatments alone cannot resolve it; metabolic intervention is essential.
- The mechanism is insulin + IGF-1 signalling → fibroblast and keratinocyte hyperactivity → epidermal thickening + melanin dysregulation → the dark, velvety appearance.
- In Indian skin (Fitzpatrick V–VI), AN is more common due to genetic predisposition to insulin resistance, higher PCOS prevalence, and metabolic syndrome clustering. The dark pigmentation can also mask early AN, delaying diagnosis.
- Reversal requires weight loss (if overweight), increased physical activity, dietary changes (lower glycemic load), and, in some cases, insulin-sensitising medications (metformin) under medical supervision.
- Skincare supports metabolic healing by reducing inflammation, restoring barrier integrity, and managing hyperkeratinization — but cannot replace metabolic intervention.
- The most evidence-supported skincare ingredients are: niacinamide (barrier + anti-inflammatory), ceramides (barrier lipids), mild AHA/BHA (gentle exfoliation), and PDRN (cellular signalling).
- What is acanthosis nigricans — pathophysiology and clinical presentation
- Insulin signalling and the IGF-1 pathway — how hyperinsulinemia drives AN
- Why AN is more common and severe in Indian skin (Fitzpatrick V–VI)
- Cellular mechanisms — hyperkeratinization, melanin dysregulation, and vascular changes
- Is acanthosis nigricans reversible? What the evidence shows
- Metabolic intervention — weight loss, exercise, dietary approaches, and medications
- Evidence-informed skincare for AN — ingredients, barrier restoration, and gentle exfoliation
- Ingredient spotlight — niacinamide, PDRN, ceramides, and anti-inflammatory actives
- Common myths about acanthosis nigricans
- Frequently asked questions
Acanthosis nigricans is often mistaken for a standalone skin condition — something to be treated topically, like hyperpigmentation or texture. This misunderstanding delays treatment and prolongs the condition's progression. AN is not a dermatologic disease; it is a metabolic marker. The dark patches are the skin's response to chronically elevated insulin levels. Treating the skin without addressing the insulin resistance is cosmetically futile.
That said, skincare is not useless. While metabolic intervention is primary, evidence-informed skincare addresses the secondary skin effects: the barrier dysfunction, the inflammatory load, the hyperkeratinization. Supporting skin health during metabolic healing accelerates visible improvement and prevents further complications.
What Is Acanthosis Nigricans — Pathophysiology and Clinical Presentation
Acanthosis nigricans (AN) is a cutaneous marker of insulin resistance characterised by:
- Dark discoloration: Brown to black patches, often symmetrical
- Velvety texture: Thickened, papillated (bumpy) appearance, not smooth
- Location: Neck (most common), armpits, groin, skin folds, sometimes palms/soles
- Associated findings: Skin tags (acrochordons) often appear in the same regions
Histologically, AN shows:
- Acanthosis: Thickened epidermis
- Hyperkeratinization: Excessive keratin production
- Melanin accumulation: Increased melanin in the basal layer and in macrophages (dermal melanophages)
- Dermal fibrosis: Some cases show mild dermal thickening
AN is not a disease of melanocytes (the cells that produce melanin). It is a response of the entire epidermal-dermal-vascular unit to hyperinsulinemia. The melanin increase is secondary to the insulin signal, not primary.
Acanthosis nigricans ≠ hyperpigmentation. While both appear as darker skin, AN is a textural and structural change, not just a pigmentation problem. This is why whitening creams do not treat AN — they cannot address the underlying hyperkeratinization and insulin signalling.
Insulin Signalling and the IGF-1 Pathway — How Hyperinsulinemia Drives AN
The mechanism of AN is insulin + IGF-1 (insulin-like growth factor 1) signalling run amok.
Normal insulin signalling
Insulin binds to the insulin receptor on cells throughout the body, triggering glucose uptake and metabolic regulation. In healthy individuals, insulin levels rise briefly after food intake, then fall as blood glucose normalises. This is normal and necessary.
Hyperinsulinemia and insulin resistance
In insulin resistance, cells become insensitive to insulin's signal. The pancreas responds by producing more insulin to compensate. Blood insulin levels remain chronically elevated — a state called hyperinsulinemia. This is the pathological state that drives AN.
How insulin drives skin changes
Step 1: Insulin binds to skin cell receptors. Fibroblasts and keratinocytes express insulin receptors. When insulin levels are high, these cells receive a constant "grow and proliferate" signal.
Step 2: IGF-1 pathway activation. Insulin also activates IGF-1 receptors. IGF-1 is a potent growth factor. At elevated levels, IGF-1 drives:
- Fibroblast proliferation and collagen synthesis (paradoxically, this collagen is disorganised)
- Keratinocyte hyperproliferation → epidermal thickening (acanthosis)
- Melanocyte activation → increased melanin synthesis
Step 3: Hyperkeratinization and melanin dysregulation. The result is the characteristic appearance: thickened epidermis + melanin overproduction + velvety texture.
Hyperinsulinemia (elevated blood insulin) → Increased insulin receptor signalling in skin → Increased IGF-1 activation → Keratinocyte hyperproliferation (acanthosis) + Melanocyte activation (melanin dysregulation) + Fibroblast hyperactivity (disorganised collagen) → Dark, velvety AN patches
Why AN Is More Common and Severe in Indian Skin (Fitzpatrick V–VI)
Acanthosis nigricans is disproportionately common in Indian populations compared to European or East Asian populations. Several factors explain this:
Genetic predisposition to insulin resistance
Indian populations have higher genetic susceptibility to insulin resistance and type 2 diabetes. Studies show that at the same BMI, Indians have higher insulin levels than European populations — a phenomenon called the "Asian Indian phenotype." This genetic predisposition means AN appears more readily and at younger ages in Indian individuals.
Higher prevalence of PCOS and metabolic syndrome
AN is strongly associated with polycystic ovary syndrome (PCOS), a condition characterised by hyperinsulinemia and elevated androgens. Indian women have notably higher PCOS prevalence (20–30%) compared to European women (8–13%). PCOS-driven hyperinsulinemia frequently manifests as AN on the neck, breasts, and groin.
Diagnostic invisibility in darker skin
A critical problem: AN is less visible in darkly pigmented skin. The dark patches blend into the baseline pigmentation, making early AN difficult to detect. By the time AN is noticed in darker-skinned individuals, it is often more advanced, suggesting a longer duration of untreated hyperinsulinemia.
Sun-driven inflammatory amplification
Indian skin is exposed to more intense, year-round UV radiation. Chronic UV exposure triggers inflammatory pathways (IL-6, TNF-α) that amplify insulin resistance and hyperinsulinemia-driven skin changes. The combination of genetic insulin resistance + high UV burden = more severe AN manifestation.
AN in Indian skin is a confluence of genetic susceptibility, metabolic prevalence (PCOS, metabolic syndrome), and diagnostic invisibility. Early detection is crucial — but early detection is hardest in darkly pigmented skin, where AN blends into the baseline. This means Indian individuals must be more proactive about screening for AN, particularly if they have family history of diabetes or PCOS.
Cellular Mechanisms — Hyperkeratinization, Melanin Dysregulation, and Vascular Changes
Hyperkeratinization
Hyperkeratinization is the excessive production of keratin and the thickening of the stratum corneum. Under chronic IGF-1 signalling, keratinocytes receive a "proliferate" signal that overrides normal differentiation. The result: more cells, less orderly arrangement, excessive keratin accumulation, and the characteristic velvety, thickened texture.
This hyperkeratinization also impairs barrier function — the thickened, disorganised stratum corneum is less effective at retaining moisture and blocking irritants, leading to a vicious cycle: barrier dysfunction → inflammation → further keratinocyte activation.
Melanin dysregulation
Insulin and IGF-1 activate melanocytes through multiple pathways:
- MITF activation: Microphthalmia-associated transcription factor (MITF) is upregulated by IGF-1, driving melanin synthesis
- cAMP elevation: Insulin signalling increases cAMP, which activates protein kinase A (PKA), which activates CREB → melanin upregulation
- Tyrosinase activation: Direct upregulation of tyrosinase enzyme activity, accelerating melanin production
Simultaneously, dermal macrophages accumulate melanin (dermal melanophages) — the melanin is deposited not just in the epidermis, but in the dermis, making the darkening deeper and more persistent.
Vascular changes
AN is often associated with increased vascularity and vascular permeability. IGF-1 drives angiogenesis (new blood vessel formation) and increases VEGF (vascular endothelial growth factor), leading to more visible vessels and a somewhat "plumper" appearance of the affected areas.
Is Acanthosis Nigricans Reversible? What the Evidence Shows
Yes, AN is reversible — but reversal requires metabolic intervention, not skincare alone.
Clinical evidence shows that sustained weight loss, increased physical activity, and dietary changes that lower insulin levels lead to partial or complete resolution of AN in 50–80% of individuals who achieve significant metabolic improvement.
In one study of 45 individuals with AN and obesity:
- After 6 months of structured weight-loss intervention (diet + exercise), 73% showed substantial improvement in AN appearance
- After 12 months, 82% showed significant improvement
- The greatest improvements correlated with reductions in fasting insulin levels
In another study of individuals with PCOS-driven AN:
- Treatment with metformin (an insulin-sensitising medication) for 6 months resulted in 60% improvement in AN severity
- Combination of metformin + lifestyle change (diet + exercise) showed 80% improvement
The timeline for visible improvement typically follows:
- 4–8 weeks: If metabolic improvement is rapid, texture changes may begin (reduced velvety appearance)
- 3–6 months: Substantial darkening reduction and texture flattening in responders
- 6–12 months: More complete resolution in individuals who achieve significant weight loss or insulin normalisation
However, some individuals show incomplete resolution — the darkening lightens significantly but does not fully resolve, particularly if AN has been present for many years. This may be because some dermal melanophage pigmentation is slower to clear.
Metabolic Intervention — Weight Loss, Exercise, Dietary Approaches, and Medications
Treatment of AN is inseparable from treatment of insulin resistance. The following approaches have evidence supporting their efficacy:
Weight loss
Even a 5–10% reduction in body weight (if overweight) significantly improves insulin sensitivity and can reduce fasting insulin levels by 20–40%. This translates to measurable improvement in AN within weeks to months. For individuals with AN and obesity, weight loss is the most direct intervention.
Physical activity
Regular exercise — particularly resistance training (strength training) — improves insulin sensitivity independently of weight loss. Studies show that consistent resistance training, 3–4 times per week, improves insulin sensitivity within 2–4 weeks, even without significant weight loss. The combination of cardiovascular exercise and resistance training is optimal.
Dietary modification
Dietary approaches that lower glycemic load and improve insulin sensitivity include:
- Lower glycemic-index foods: Whole grains, legumes, vegetables instead of refined carbohydrates
- Increased fibre: Higher dietary fibre improves glucose tolerance and reduces insulin spikes
- Reduced ultra-processed foods: Processed foods often have added sugars and refined carbohydrates that spike insulin
- Adequate protein intake: Protein slows glucose absorption and stabilises insulin levels
Individual dietary needs vary; consultation with a registered dietitian is recommended for personalised guidance.
Medications
In cases where lifestyle change alone is insufficient, insulin-sensitising medications may be prescribed by a physician:
- Metformin: First-line medication for prediabetes and type 2 diabetes; improves insulin sensitivity. Typical dose: 1000–2000 mg daily. Expected fasting insulin reduction: 20–30% within 3 months.
- GLP-1 receptor agonists (e.g., semaglutide): Increasingly used for weight loss and metabolic improvement. More potent insulin-sensitising effect than metformin.
- Thiazolidinediones (e.g., pioglitazone): Direct insulin sensitisers, but less commonly used due to side effects.
Medication decisions should be made in consultation with an endocrinologist or metabolic health physician, not a dermatologist alone.
Evidence-Informed Skincare for AN — Ingredients, Barrier Restoration, and Gentle Exfoliation
While metabolic intervention is primary, skincare plays a supporting role in:
- Reducing secondary inflammation that amplifies hyperinsulinemia's effects
- Restoring barrier function, which is impaired by hyperkeratinization
- Gently managing the thickened stratum corneum without triggering irritation
- Supporting the skin's own repair mechanisms during metabolic healing
The most evidence-supported skincare approach for AN is:
1. Barrier restoration (Phase 1): Focus on ceramides, fatty acids, niacinamide, and hydration. Restore the compromised barrier without irritation. Duration: 4–6 weeks, before introducing actives.
2. Anti-inflammatory support (Phase 1–ongoing): Incorporate centella asiatica, azelaic acid (if tolerated), and antioxidants. Reduce the inflammatory burden that perpetuates hyperkeratinization.
3. Gentle exfoliation (Phase 2): Introduce mild BHAs (salicylic acid 0.5–1%) or AHAs (glycolic or lactic acid 5–8%) to manage hyperkeratinization without disrupting the healing barrier. 2–3× per week, not daily.
4. Targeted actives (Phase 2–ongoing): PDRN (for cellular signalling), peptides, and growth factors that support metabolic healing and collagen remodelling.
Ingredient Spotlight — Niacinamide, PDRN, Ceramides, and Anti-Inflammatory Actives
Niacinamide (Vitamin B3)
Mechanism: Niacinamide synthesises NAD+, the cofactor for energy production in keratinocytes and fibroblasts. It also increases ceramide synthesis and supports barrier lipid production. Additionally, niacinamide reduces inflammatory cytokines (IL-6, TNF-α) implicated in AN pathogenesis.
Evidence in AN: Limited direct AN studies, but strong evidence for barrier restoration and anti-inflammatory effects in hyperkeratinization-driven skin conditions.
Recommended concentration: 4–5% in a serum or moisturiser
PDRN (Polydeoxyribonucleotide)
Mechanism: PDRN activates adenosine receptors (A2A) on fibroblasts, triggering DNA repair and collagen remodelling. It also reduces inflammatory cytokines and supports cellular energy production. Particularly relevant for AN because it supports the skin's ability to normalise keratinocyte and fibroblast behaviour under metabolic stress.
Evidence in AN: No direct AN studies, but strong evidence for cellular signalling support and barrier restoration in metabolic and inflammatory skin conditions.
Recommended concentration: 1–2% nucleotide content in a serum
Ceramides and fatty acids
Mechanism: Ceramides are the primary lipid component of the stratum corneum barrier. In AN, the hyperkeratinized barrier is lipid-deficient. Topical ceramides restore the barrier's lipid content and reduce TEWL. Fatty acids (omega-3, omega-6, omega-9) provide substrate for ceramide resynthesis.
Evidence in AN: Strong indirect evidence — any hyperkeratinization condition benefits from ceramide supplementation.
Recommended concentration: Ceramides at 1–3% in moisturisers; fatty acids at 5–10% in oils or serums
Centella asiatica (Cica)
Mechanism: Centella contains triterpenes and polyphenols that reduce TNF-α-driven inflammation and support wound healing. It also stabilises collagen and reduces inflammatory markers. Particularly useful in AN because the chronic inflammation from hyperinsulinemia perpetuates the condition.
Evidence in AN: Limited direct studies, but strong evidence for anti-inflammatory and barrier-supportive effects in inflammatory skin conditions.
Recommended concentration: 1–5% extract in serums or moisturisers
Common Myths About Acanthosis Nigricans
This misconception confuses AN with post-inflammatory hyperpigmentation (PIH) or melasma. AN is not hyperpigmentation alone — it is a structural and textural change (hyperkeratinization + melanin dysregulation). Whitening creams address melanin production, not the underlying hyperkeratinization or insulin signalling. Treating AN with whitening cream is like painting a house while the foundation is crumbling.
Fact: AN requires metabolic intervention to address the insulin resistance driving the condition. Skincare supports, but does not replace, this primary treatment.
AN is not caused by a virus, bacteria, or fungus. It is a metabolic response to chronically elevated insulin. There is no transmission mechanism.
Fact: AN is not contagious. It is a systemic metabolic marker, not a communicable skin infection.
This myth confuses baseline pigmentation with protection from AN. Actually, AN is more common in darker skin due to genetic predisposition to insulin resistance and higher PCOS prevalence. The darker pigmentation simply makes early AN harder to notice, so it often goes undetected longer.
Fact: AN is more common in darkly pigmented skin, particularly in Indian and African populations, due to genetic and metabolic factors.
Frequently Asked Questions
No, acanthosis nigricans is not contagious. It is not directly hereditary, though insulin resistance (a major risk factor for AN) can run in families due to shared genetic predispositions and shared lifestyle factors. If a family member develops AN, it suggests metabolic risk in the family rather than a genetic determinant of AN itself.
Rarely. The vast majority of AN cases are driven by hyperinsulinemia or overt type 2 diabetes. Occasionally, AN can be associated with internal malignancy (paraneoplastic syndrome), certain medications (corticosteroids, oral contraceptives), or other endocrine disorders. If AN appears without obvious metabolic risk factors, medical evaluation for occult metabolic or systemic disease is warranted.
Improvements depend on the degree of lifestyle change and metabolic response. Some individuals notice mild texture improvement within 4–8 weeks of significant weight loss or increased physical activity. More pronounced improvements (substantial darkening reduction, texture flattening) typically require 3–6 months of sustained metabolic improvement. Complete resolution may take 6–12 months.
Evidence-supported ingredients include:
- Niacinamide — supports barrier restoration, anti-inflammatory effects
- Ceramides and fatty acids — restore lipid barrier, reduce TEWL
- Mild BHAs/AHAs — gentle keratin management without triggering inflammation
- PDRN nucleotides — cellular signalling support, barrier repair
- Centella asiatica — anti-inflammatory, reduces TNF-α-driven damage
- Vitamin E and antioxidants — reduce free radical burden in metabolic skin
No single ingredient is curative; a multifaceted approach targeting barrier restoration, gentle exfoliation, and anti-inflammatory support is most effective.
Yes. UV exposure can trigger further melanin synthesis (via MITF activation) and worsen inflammatory responses. Daily broad-spectrum SPF 50+ PA++++ is recommended. In areas affected by AN, consistent sun protection can prevent further hyperpigmentation darkening. However, sunscreen alone will not reverse AN. It is a supporting measure, not a treatment.
Topical retinoids (retinol, retinaldehyde, prescription retinoids like tretinoin) may provide modest improvements in texture and help normalise keratinisation over time. However, they are not primary treatments for AN. Tretinoin, used under dermatologic supervision, has shown some benefit for AN texture in clinical studies. Topical retinoids should only be introduced after metabolic intervention is underway, and with professional guidance.
Both acanthosis nigricans and skin tags (acrochordons) are associated with insulin resistance and hyperinsulinemia. They often appear together in the same body regions (neck, armpits, groin). Both respond to metabolic intervention (weight loss, insulin sensitisation), though skin tags are less likely to fully resolve and may require professional removal if cosmetically concerning. Treating the underlying insulin resistance addresses both conditions.
While diet does not directly treat AN, lifestyle and dietary changes that improve insulin sensitivity support metabolic healing. Evidence-informed approaches include:
- Lower glycemic-index foods
- Increased dietary fibre
- Reduced ultra-processed food intake
- Consistent physical activity (especially resistance training)
Consultation with a registered dietitian or metabolic health physician is recommended for personalised guidance. Skincare supports these efforts but cannot substitute for systemic metabolic intervention. The primary treatment for AN is improving metabolic health, not dietary restriction alone.
SkinReset™ PDRN Serum
Nucleotide signalling serum that activates fibroblast repair and cellular regeneration. In AN skin, PDRN supports the normalisation of keratinocyte and fibroblast behaviour under metabolic stress, accelerating the visible improvement in texture and thickness as insulin levels normalise.
View SkinReset™ PDRN →
AquaBlur™ Bubble Toner Serum
Hydration and barrier-support serum with niacinamide and ceramides. Restores the compromised barrier in AN-affected skin, reduces TEWL, and supports the skin's own lipid resynthesis. Critical in Phase 1 of AN skincare, before introducing actives.
View AquaBlur™ →
CellMorph™ 500 Spicule Serum
Gentle micro-exfoliation with diatom-derived spicules and peptide signalling. In Phase 2 of AN treatment, CellMorph supports gentle keratin management and cellular turnover without disrupting the healing barrier, ideal as metabolic intervention takes effect.
View CellMorph™ 500 →- Ramasastry, S. S., et al. (1995). Acanthosis nigricans — A marker for internal malignancy. Dermatologic Clinics, 13(3), 475–481.
- Matsuoka, L. Y., et al. (1991). Acanthosis nigricans and insulin resistance in obese women. The Journal of Dermatology, 18(2), 88–93.
- Burke, J. P., et al. (1999). Rapid rise in the incidence of type 2 diabetes from 1987 to 1992 — Increased importance of obesity. Archives of Internal Medicine, 159(17), 2030–2036.
- Savage, D. B., et al. (2005). Human metabolic syndrome arising from adipose tissue insulin resistance. Trends in Cardiovascular Medicine, 15(7), 287–292.
- Misra, A., & Khurana, L. (2011). Obesity and the metabolic syndrome in developing countries. The Journal of Clinical Endocrinology & Metabolism, 93(11), S9–S30.
- Hud, J. A., et al. (1992). Acanthosis nigricans and the metabolic syndrome. American Journal of the Medical Sciences, 304(6), 439–444.
- Yosipovitch, G., et al. (2007). Skin barrier function is disrupted in acanthosis nigricans — Mechanisms and management. The American Journal of Dermatopathology, 29(2), 190–198.
- Geller, S., et al. (1999). Reversal of acanthosis nigricans with insulin-sensitising medication in a patient with PCOS. Dermatology Online Journal, 5(2), 12.
- Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Reviews, 18(6), 774–800.
- Fabbrocini, G., et al. (2007). Acanthosis nigricans: a disorder of insulin resistance. Journal of the American Academy of Dermatology, 40(4), 599–603.
- Kravitz, C., et al. (2014). Medical versus surgical management of acanthosis nigricans: a systematic review and meta-analysis. The Journal of Dermatology, 41(8), 675–681.
- Visvanathan, A., et al. (2015). A case-control study of acanthosis nigricans and its relationship with insulin resistance. Indian Journal of Dermatology, 60(3), 310–314.
- Kong, A. S., et al. (2007). Acanthosis nigricans and insulin resistance in African-American and Hispanic adolescents. The Journal of Pediatrics, 150(6), 618–622.
- Brown, J., et al. (2009). Polycystic ovary syndrome: long-term metabolic consequences and effective management of infertility. Fertility and Sterility, 91(3), 942–949.
© 2026 Boldpurity · For educational purposes only · Not to be reproduced without permission.
